Vera Therapeutics News and Activities

Vera Therapeutics is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Vera Therapeutics is a company listed under the stock ticker VERA (US).

View the org chart displaying its 31 main executives

Most searched biographies at Vera Therapeutics

• Marshall Fordyce, Chief Executive Officer and Director
• Maha Katabi, Director
• Andrew Cheng, Director

Popular executive movements at Vera Therapeutics

• Jane Wright-Mitchell has joined the company as Chief Legal Officer  (posted on March 25 2026).
• Christopher Hite has joined the company as Director  (posted on March 9 2026).
• Matt Skelton, who was Executive Vice President, Commercial, is promoted to Chief Commercial Officer  (posted on January 29 2026).

Click here to view some more movements at Vera Therapeutics

Create your alert
to follow the executive moves at Vera Therapeutics.

Vera Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Vera Therapeutics

• Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 | Vera Therapeutics
• Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 | Vera Therapeutics
• Vera Therapeutics to Participate at September Investor Conferences | Vera Therapeutics
• Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress | Vera Therapeutics
• Vera Therapeutics Launches with $80 Million Series C Financing to Develop Phase 2b Novel Biologic for Kidney Disease • Vera Therapeutics
• Vera Therapeutics Appoints Industry Veteran Dr. Celia Lin as Chief Medical Officer • Vera Therapeutics
• News • Vera Therapeutics
• View more press releases Close

Social media about Vera Therapeutics

• Vera Therapeutics on Wikipedia, Google News & Yahoo Finance
• Vera Therapeutics on LinkedIn, X (Twitter) & YouTube